Patient Age/Gender: Unknown Unknown Printed: 17-Jun-19 09:46:56

<u>Procedure</u> Mi-2 (nuclear helicase protein) Antibody	Result Positive	*	<u>Units</u>	<u>Ref Interval</u> [Negative]	Reported/ Accession Collected Received Verified 19-161-900135 10-Jun-19 10-Jun-19 11-Jun-19 12:14:00 12:14:100 08:13:10
P155/140 Antibody	Negative			[Negative]	19-161-900135 10-Jun-19 10-Jun-19 11-Jun-19 12:14:00 12:14:00 08:13:10
TIF-1 gamma (155 kDa) Ab	Negative				19-161-900135 10-Jun-19 10-Jun-19 12:14:00 08:13:10 12:14:00 12:14:00 08:13:10
SAE1 (SUMO activating enzyme) Ab	Positive	*			19-161-900135 10-Jun-19 10-Jun-19 11-Jun-19
MDA5 (CADM-140) Ab	Negative				12:14:00 12:14:00 08:13:10 19-161-900135 10-Jun-19 10-Jun-19 11-Jun-19 12:14:00 12:14:00 08:13:10
NXP2 (Nuclear matrix protein-2) Ab	Negative				19-161-900135 10-Jun-19 10-Jun-19 11-Jun-19
Dermatomyositis Interpretive Information	See Note				12:14:00 12:14:00 08:13:10 19-161-900135 10-Jun-19 10-Jun-19 11-Jun-19 12:14:00 12:14:00 08:13:10

10-Jun-19 12:14:00 Dermatomyositis Interpretive Information: INTERPRETIVE INFORMATION: Dermatomyositis Autoantibody Panel

If present, myositis-specific antibodies (MSA) are specific for myositis, and may be useful in establishing diagnosis as well as prognosis. MSAs are generally regarded as mutually exclusive with rare exceptions; the occurrence of two or more MSAs should be carefully evaluated in the context of patient's clinical presentation. Myositisassociated antibodies (MAA) may be found in patients with CTD including overlap syndromes, and are generally not specific for myositis. The following table will help in identifying the association of any antibodies found as either MSAs or MAAs.

Antibody SpecificityMAAMi-2 (nuclear helicase protein)AntibodyXP155/140 AntibodyXTIF-1 gamma (155 kDa)AbXSAE1 (SUMO activating enzyme)AbXMDA5 (CADM-140)AbXNXP2 (Nuclear matrix proten-2)AbX

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS